Logo image
Back
Therapeutic strategies for a functional cure of chronic hepatitis B virus infection
Journal article   Open access   Peer reviewed

Therapeutic strategies for a functional cure of chronic hepatitis B virus infection

Jinhong Chang, Fang Guo, Xuesen Zhao and Ju-Tao Guo
Acta pharmaceutica Sinica. B, v 4(4)
18 Jun 2014
DOI: https://doi.org/10.1016/j.apsb.2014.05.002
PMID: 26579392
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1016/j.apsb.2014.05.002View
Published, Version of Record (VoR)CC BY-NC-ND V4.0,  Open

Abstract

Antiviral agents cccDNA Hepatitis B virus Review
Treatment of chronic hepatitis B virus (HBV) infection with the viral DNA polymerase inhibitors or pegylated alpha-interferon has led to a significant retardation in HBV-related disease progression and reduction in mortality related to chronic hepatitis B associated liver decompensation and hepatocellular carcinoma. However, chronic HBV infection remains not cured. The reasons for the failure to eradicate HBV infection by long-term antiviral therapy are not completely understood. However, clinical studies suggest that the intrinsic stability of the nuclear form of viral genome, the covalently closed circular (ccc) DNA, sustained low level viral replication under antiviral therapy and homeostatic proliferation of hepatocytes are the critical virological and pathophysiological factors that affect the persistence and therapeutic outcomes of HBV infection. More importantly, despite potent suppression of HBV replication in livers of the treated patients, the dysfunction of HBV-specific antiviral immunity persists. The inability of the immune system to recognize cells harboring HBV infection and to cure or eliminate cells actively producing virus is the biggest challenge to finding a cure. Unraveling the complex virus–host interactions that lead to persistent infection should facilitate the rational design of antivirals and immunotherapeutics to cure chronic HBV infection. Therapeutic goal of chronic hepatitis B is a “functional” cure of HBV infection, which is rarely achieved with currently available antiviral agents. Major obstacles to a functional cure are intricate stability of HBV cccDNA and dysfunctional anti-HBV immune response. Antiviral and immunotherapeutic strategies to achieve a functional cure are proposed.

Metrics

6 Record Views
50 citations in Web of Science

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Pharmacology & Pharmacy
Logo image